Potential impact of tariffs on active pharmaceutical ingredients on the price of US-made generic drugs
Tariffs could raise costs for US drug manufacturers using imported APIs, potentially limiting affordability and manufacturers' competitiveness in United States and global markets. Policies to incentivize "made-in-America" prescription drugs should incentivize domestic API production or reconsider API tariffs.
Authors
- Mariana P. Socal (ORCID: https://orcid.org/0000-0001-9459-4898)
- Yunpeng Sun (ORCID: https://orcid.org/0000-0002-2811-8946)
- Maqbool Dada (ORCID: https://orcid.org/0000-0002-5256-1446)
- Joy Acha
- Jeromie M. Ballreich
- Tinglong Dai
- Mohammad Ali Yazdi
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Health Affairs Scholar
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1093/haschl/qxaf247
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00